(HCA) HCA Holdings - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US40412C1018
Hospital, Outpatient, Surgery, Imaging, Behavioral
Dividends
| Dividend Yield | 0.59% |
| Yield on Cost 5y | 1.87% |
| Yield CAGR 5y | 36.07% |
| Payout Consistency | 53.8% |
| Payout Ratio | 10.9% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 29.0% |
| Value at Risk 5%th | 47.1% |
| Relative Tail Risk | -1.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.59 |
| Alpha | 47.08 |
| CAGR/Max DD | 0.98 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.598 |
| Beta | 0.291 |
| Beta Downside | 0.430 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.45% |
| Mean DD | 8.39% |
| Median DD | 5.68% |
Description: HCA HCA Holdings December 02, 2025
HCA Healthcare, Inc. (NYSE:HCA) operates a nationwide network of acute-care hospitals and a broad suite of outpatient facilities-including ambulatory surgery centers, urgent-care clinics, imaging centers, and behavioral health hospitals-providing services from inpatient and intensive care to outpatient diagnostics and rehabilitation.
As of FY 2023, HCA reported $20.1 billion in revenue with an adjusted EBITDA margin of roughly 15%, driven by a 4.2% year-over-year increase in inpatient admissions and a 3.8% rise in outpatient volume. The company’s average occupancy rate sits near 71%, slightly above the industry average of 68%, reflecting strong demand for both acute and specialty services.
Key macro-drivers for HCA include the aging U.S. population, which fuels higher utilization of cardiac and orthopedic procedures, and ongoing Medicare-DRG reimbursement reforms that pressure margins. Additionally, labor shortages in nursing and allied health professions remain a cost headwind, prompting the firm to invest in automation and workforce retention programs.
For a deeper quantitative view, you might explore the ValueRay platform’s hospital profitability metrics.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (6.38b TTM) > 0 and > 6% of Revenue (6% = 4.46b TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA 3.66pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -3.51% (prev 2.53%; Δ -6.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.21 (>3.0%) and CFO 12.84b > Net Income 6.38b (YES >=105%, WARN >=100%) |
| Net Debt (45.35b) to EBITDA (15.00b) ratio: 3.02 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (242.5m) change vs 12m ago -6.72% (target <= -2.0% for YES) |
| Gross Margin 15.64% (prev 15.08%; Δ 0.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 124.8% (prev 117.1%; Δ 7.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.23 (EBITDA TTM 15.00b / Interest Expense TTM 2.20b) >= 6 (WARN >= 3) |
Altman Z'' 0.65
| (A) -0.04 = (Total Current Assets 15.29b - Total Current Liabilities 17.90b) / Total Assets 59.75b |
| (B) -0.08 = Retained Earnings (Balance) -5.03b / Total Assets 59.75b |
| (C) 0.19 = EBIT TTM 11.53b / Avg Total Assets 59.60b |
| (D) -0.09 = Book Value of Equity -5.33b / Total Liabilities 61.91b |
| Total Rating: 0.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.04
| 1. Piotroski 7.50pt |
| 2. FCF Yield 5.08% |
| 3. FCF Margin 10.89% |
| 4. Debt/Equity -8.69 |
| 5. Debt/Ebitda 3.02 |
| 6. ROIC - WACC (= 17.31)% |
| 7. RoE -161.9% |
| 8. Rev. Trend 97.85% |
| 9. EPS Trend 84.75% |
What is the price of HCA shares?
As of December 14, 2025, the stock is trading at USD 484.77 with a total of 854,107 shares traded.
Over the past week, the price has changed by -0.40%, over one month by +2.36%, over three months by +19.87% and over the past year by +56.64%.
Over the past week, the price has changed by -0.40%, over one month by +2.36%, over three months by +19.87% and over the past year by +56.64%.
Is HCA a buy, sell or hold?
HCA Holdings has received a consensus analysts rating of 4.08.
Therefore, it is recommended to buy HCA.
- Strong Buy: 13
- Buy: 2
- Hold: 9
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the HCA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 477.7 | -1.5% |
| Analysts Target Price | 477.7 | -1.5% |
| ValueRay Target Price | 638.3 | 31.7% |
HCA Fundamental Data Overview December 06, 2025
Market Cap USD = 114.11b (114.11b USD * 1.0 USD.USD)
P/E Trailing = 18.865
P/E Forward = 16.4474
P/S = 1.5343
P/B = 293.44
P/EG = 1.2973
Beta = 1.376
Revenue TTM = 74.37b USD
EBIT TTM = 11.53b USD
EBITDA TTM = 15.00b USD
Long Term Debt = 38.40b USD (from longTermDebt, last quarter)
Short Term Debt = 6.11b USD (from shortTermDebt, last quarter)
Debt = 46.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 45.35b USD (from netDebt column, last quarter)
Enterprise Value = 159.46b USD (114.11b + Debt 46.35b - CCE 997.0m)
Interest Coverage Ratio = 5.23 (Ebit TTM 11.53b / Interest Expense TTM 2.20b)
FCF Yield = 5.08% (FCF TTM 8.10b / Enterprise Value 159.46b)
FCF Margin = 10.89% (FCF TTM 8.10b / Revenue TTM 74.37b)
Net Margin = 8.57% (Net Income TTM 6.38b / Revenue TTM 74.37b)
Gross Margin = 15.64% ((Revenue TTM 74.37b - Cost of Revenue TTM 62.74b) / Revenue TTM)
Gross Margin QoQ = 15.47% (prev 15.95%)
Tobins Q-Ratio = 2.67 (Enterprise Value 159.46b / Total Assets 59.75b)
Interest Expense / Debt = 1.21% (Interest Expense 561.0m / Debt 46.35b)
Taxrate = 21.06% (516.0m / 2.45b)
NOPAT = 9.10b (EBIT 11.53b * (1 - 21.06%))
Current Ratio = 0.85 (Total Current Assets 15.29b / Total Current Liabilities 17.90b)
Debt / Equity = -8.69 (negative equity) (Debt 46.35b / totalStockholderEquity, last quarter -5.33b)
Debt / EBITDA = 3.02 (Net Debt 45.35b / EBITDA 15.00b)
Debt / FCF = 5.60 (Net Debt 45.35b / FCF TTM 8.10b)
Total Stockholder Equity = -3.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.67% (Net Income 6.38b / Total Assets 59.75b)
RoE = -161.9% (negative equity) (Net Income TTM 6.38b / Total Stockholder Equity -3.94b)
RoCE = 33.45% (EBIT 11.53b / Capital Employed (Equity -3.94b + L.T.Debt 38.40b))
RoIC = 22.63% (NOPAT 9.10b / Invested Capital 40.21b)
WACC = 5.32% (E(114.11b)/V(160.46b) * Re(7.09%) + D(46.35b)/V(160.46b) * Rd(1.21%) * (1-Tc(0.21)))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -5.44%
[DCF Debug] Terminal Value 80.13% ; FCFE base≈7.21b ; Y1≈8.25b ; Y5≈11.48b
Fair Price DCF = 869.4 (DCF Value 198.39b / Shares Outstanding 228.2m; 5y FCF grow 16.94% → 3.0% )
EPS Correlation: 84.75 | EPS CAGR: 12.87% | SUE: 3.43 | # QB: 3
Revenue Correlation: 97.85 | Revenue CAGR: 6.63% | SUE: 1.97 | # QB: 1
EPS next Quarter (2026-03-31): EPS=7.19 | Chg30d=+0.190 | Revisions Net=+5 | Analysts=13
EPS next Year (2026-12-31): EPS=29.75 | Chg30d=+0.625 | Revisions Net=+15 | Growth EPS=+7.6% | Growth Revenue=+4.5%
P/E Trailing = 18.865
P/E Forward = 16.4474
P/S = 1.5343
P/B = 293.44
P/EG = 1.2973
Beta = 1.376
Revenue TTM = 74.37b USD
EBIT TTM = 11.53b USD
EBITDA TTM = 15.00b USD
Long Term Debt = 38.40b USD (from longTermDebt, last quarter)
Short Term Debt = 6.11b USD (from shortTermDebt, last quarter)
Debt = 46.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 45.35b USD (from netDebt column, last quarter)
Enterprise Value = 159.46b USD (114.11b + Debt 46.35b - CCE 997.0m)
Interest Coverage Ratio = 5.23 (Ebit TTM 11.53b / Interest Expense TTM 2.20b)
FCF Yield = 5.08% (FCF TTM 8.10b / Enterprise Value 159.46b)
FCF Margin = 10.89% (FCF TTM 8.10b / Revenue TTM 74.37b)
Net Margin = 8.57% (Net Income TTM 6.38b / Revenue TTM 74.37b)
Gross Margin = 15.64% ((Revenue TTM 74.37b - Cost of Revenue TTM 62.74b) / Revenue TTM)
Gross Margin QoQ = 15.47% (prev 15.95%)
Tobins Q-Ratio = 2.67 (Enterprise Value 159.46b / Total Assets 59.75b)
Interest Expense / Debt = 1.21% (Interest Expense 561.0m / Debt 46.35b)
Taxrate = 21.06% (516.0m / 2.45b)
NOPAT = 9.10b (EBIT 11.53b * (1 - 21.06%))
Current Ratio = 0.85 (Total Current Assets 15.29b / Total Current Liabilities 17.90b)
Debt / Equity = -8.69 (negative equity) (Debt 46.35b / totalStockholderEquity, last quarter -5.33b)
Debt / EBITDA = 3.02 (Net Debt 45.35b / EBITDA 15.00b)
Debt / FCF = 5.60 (Net Debt 45.35b / FCF TTM 8.10b)
Total Stockholder Equity = -3.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.67% (Net Income 6.38b / Total Assets 59.75b)
RoE = -161.9% (negative equity) (Net Income TTM 6.38b / Total Stockholder Equity -3.94b)
RoCE = 33.45% (EBIT 11.53b / Capital Employed (Equity -3.94b + L.T.Debt 38.40b))
RoIC = 22.63% (NOPAT 9.10b / Invested Capital 40.21b)
WACC = 5.32% (E(114.11b)/V(160.46b) * Re(7.09%) + D(46.35b)/V(160.46b) * Rd(1.21%) * (1-Tc(0.21)))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -5.44%
[DCF Debug] Terminal Value 80.13% ; FCFE base≈7.21b ; Y1≈8.25b ; Y5≈11.48b
Fair Price DCF = 869.4 (DCF Value 198.39b / Shares Outstanding 228.2m; 5y FCF grow 16.94% → 3.0% )
EPS Correlation: 84.75 | EPS CAGR: 12.87% | SUE: 3.43 | # QB: 3
Revenue Correlation: 97.85 | Revenue CAGR: 6.63% | SUE: 1.97 | # QB: 1
EPS next Quarter (2026-03-31): EPS=7.19 | Chg30d=+0.190 | Revisions Net=+5 | Analysts=13
EPS next Year (2026-12-31): EPS=29.75 | Chg30d=+0.625 | Revisions Net=+15 | Growth EPS=+7.6% | Growth Revenue=+4.5%
Additional Sources for HCA Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle